Canada markets close in 5 hours 11 minutes
  • S&P/TSX

    +199.39 (+1.00%)
  • S&P 500

    +31.67 (+0.75%)
  • DOW

    +265.42 (+0.80%)

    +0.0013 (+0.17%)

    +0.39 (+0.42%)

    +490.34 (+1.59%)
  • CMC Crypto 200

    +3.00 (+0.52%)

    -5.40 (-0.30%)
  • RUSSELL 2000

    +32.64 (+1.66%)
  • 10-Yr Bond

    +0.0430 (+1.54%)

    +81.37 (+0.63%)

    +0.05 (+0.25%)
  • FTSE

    -32.73 (-0.44%)
  • NIKKEI 225

    -180.63 (-0.65%)

    -0.0011 (-0.14%)

Parabolic Returns in 2022 Are Possible From 3 Growth Stocks

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Written by Christopher Liew, CFA at The Motley Fool Canada

Rising interest rates affect businesses — more so for growth-oriented companies. Technology is the hardest-hit sector in an inflationary period, as tech companies rely on borrowing to pursue growth initiatives. However, there are exceptions. Some companies — not only in tech but in other sectors — are doing well amid inflationary pressures.

Sierra Wireless (TSX:SW)(NASDAQ:SWIR), Bellus Health (TSX:BLU)(NASDAQ:BLU), and Exchange Income (TSX:EIF) have survived the market selloff. All three stocks should be on the buy lists of growth investors.


Sierra Wireless ($30.15 per share) outperforms the broader market year to date at +35.2% versus -11.13%. Also, the tech stock has done well in 3.01 years, as evidenced by the 90.22% (23.83% CAGR). The $1.15 billion company provides device-to-cloud Internet of Things (IoT) solutions globally.

In Q1 2022, revenue grew 61% to US$173 million versus Q1 2021. Phil Brace, Sierra’s president and CEO, said, “We delivered strong sequential and year-over-year growth in the first quarter. We continue to work closely with our suppliers to secure components to meet the strong demand from our customers.”

The US$13.9 million net loss from operations for the quarter was a 51% improvement from US$28.5 million net loss in the same quarter last year. Sierra’s adjusted earnings from operations reached US$8.6 million compared to the US$9.6 million net loss from a year ago.

For Q2 2022, management expects revenue between US$160 million and US$175 million. Because of the continued strong demand and the investment in inventory to combat the industry-wide supply tightness, the projection is achievable.


As of July 1, 2022, healthcare is worst-performing sector with its nearly 50% year-to-date loss. However, Bellus Health continues to fly high. At $11.85 per share, the trailing one-year price return is 207.79%, while the year-to-date gain is 16.52%. The 12-month average price target of market analysts is $15.52 (+30.9%).

The $1.26 billion clinical-stage biopharmaceutical company develops novel therapeutics for the treatment of RCC and other cough hypersensitivity indications. Its lead product candidate and potential growth driver is BLU-5937. The Phase 2b trial was a successful and the Phase 3 program will commence in the second half of 2022.

Roberto Bellini, president and CEO of BELLUS Health, envisions BLU-5937 to be the best-in-class treatment for refractory chronic cough (RCC). He said, “The need for chronic cough treatments remains high and we are determined to fill this gap in care with a differentiated treatment option for the patients affected.”


Exchange Income isn’t a high flyer, although market analysts covering the industrial stock recommends a buy rating and forecast a 38.8% appreciation from its current share price of $42.14 (+2.76% year to date). The overall return in 12 months should be higher if you include the hefty 5.70% dividend.

The $1.66 billion company reported record revenue ($400.22 million) in Q1 2022, which represents a 33% increase from Q1 2021. Exchange Income boasts diversified operations and is acquisition oriented. It generates steady cash flow from niche markets in the aerospace & aviation services and equipment, and manufacturing sectors.

Parabolic returns

Thus far in 2022, Sierra Wireless, Bellus Health, and Exchange Income have not disappointed investors. Barring any massive disruptions in their continuing growth efforts, the potential returns in one year could be parabolic.

The post Parabolic Returns in 2022 Are Possible From 3 Growth Stocks appeared first on The Motley Fool Canada.

Should You Invest $1,000 In Bellus Health?

Before you consider Bellus Health, we think you’ll want to hear this.

Our nearly S&P/TSX market doubling* Stock Advisor Canada team just released their top 10 starter stocks for 2022 that we believe could supercharge any portfolio.

Want to see if Bellus Health made our list? Get started with Stock Advisor Canada today to receive all 10 of our starter stocks, a fully stocked treasure trove of industry reports, two brand-new stock recommendations every month, and much more.

See the 10 Stocks * Returns as of 4/14/22

More reading

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting